

WHO WE ARE: ChemDiv is a fully integrated, target-to-clinic global contract research organization serving life sciences clients. Headquartered in the world-famous San Diego biotechnology hub, we have offices and operations in the major innovation clusters and centers of excellence throughout the US, Europe and Asia.

Since it began assembling diverse heterocyclic compound collections from academic labs across the globe in 1991, ChemDiv has been a pioneer in the discovery chemistries revolution. We are now the recognized global leader in discovery chemistry and have the industry's largest, most diverse and most pharmacologically-relevant commercial collection of over 1,500,000 individually crafted, lead-like, drug-like small molecules.

ChemDiv continues to lead the industry with our large-scale library synthesis programs, defining and opening up promising new and sophisticated chemistry space. We are also a scientific leader in the design and validation of sophisticated scaffolds, templates and MedChem compounds.

20 YEARS OF SUCCESS IN THE LIFE SCIENCES

Building on our strong 20-year track record of success, ChemDiv today offers integrated Discovery outSource™ solutions encompassing all disciplines needed to bring your project from target ID to Phase III clinical candidate and beyond. Enabling these services are our 600-plus professionals working in state-of-the-art modern facilities and supported by outstanding global logistics operations.

We are honored to have worked with more than 2,500 customers and collaborators, ranging from large, midsized and small pharma/ biotechs to internationally recognized universities, foundations and research centers.

WHAT WE DO: ChemDiv executes pre-clinical chemistry and biology projects and clinical trials for an international portfolio of drug development companies across the entire range of targets including small molecules and biologics.

We operate multiple research and development (R&D) subsidiaries in Russia, Ukraine and China, as well as business operations around the world.

We pride ourselves on being one of the industry's most experienced CROs, with hands-on expertise in every aspect of discovery, pre-clinical and clinical development of anti-infectives and antivirals, and oncologics, central nervous system (CNS), cardiometabolics, and anti-inflammatory therapies.

Our track record spans successful and timely delivery of discovery and target-biased compound libraries reflective of modern trends in chemical biology, medicinal chemistry, pathway analysis, structural biology, molecular modeling, and biochemical, cellular and in vivo assay development and scale-up. We also offer a comprehensive selection of modern drug discovery and evaluation platforms and ADME/ tox models, all aimed at accelerated, cost-effective R&D.

In addition to specialized and vertically integrated services, we offer our partners more efficient use of capital, strong risk mitigation, and access to our drug development expertise. We have a number of flexible business models with competitive pricing options that help clients manage development risk, conserve their R&D budgets, and appropriately reward successful development outcomes.


FOR MORE INFORMATION:

6605 Nancy Ridge Drive San Diego, CA 82121 Phone: (858) 894-4860 Fax: (858) 794-4931 Email: chemdiv@chemdiv.com

www.chemdiv.com



The ChemDiv Difference



- Cost-effective quality systems, 100% compliant with 'GLP-like', GLP, and GCP standards, and local legislation.
- Optimal discovery and development processes generating high-quality project data that enable fast-forward/fast-fail decisions.
- Ongoing capital investment in state-of-the-art facilities, chemistries and platforms.
- Chemistry on Demand[™] rapid hit and lead expansion, SAR & chem space characterization.
- Discovery outSourceSM highly efficient, integrated chemistry & biology discovery solutions.
- Time- and cost-efficient candidate development and qualification.
- IND-enabling pre-clinical studies and drug formulation capabilities.
- Complimentary feasibility assessment of clinical trial enrollment, duration, number of sites for a given protocol, synopsis, or study outline.
- Shortest timelines for study documents and dossier preparation, enabling quick patient enrollments and minimizing delays in regulatory approval (on average 10-12 weeks after submission).
- Experienced in Phase I-IV studies in a wide range of therapeutic indications.







FOR MORE INFORMATION:

6605 Nancy Ridge Drive San Diego, CA 82121 Phone: (858) 894-4860

Fax: (858) 794-4931 Email: chemdiv@chemdiv.com www.chemdiv.com